Search

Your search keyword '"Morel, O. (Olivier)"' showing total 2 results
Start Over Author "Morel, O. (Olivier)"
2 results on '"Morel, O. (Olivier)"'

1. Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: Role of endothelial SGLT1 and 2

Author

Bruckert, C. (Christophe), Matsushita, K. (Kensuke), Mroueh, A. (Ali), Amissi, S. (Said), Auger, C. (Cyril), Hounguè, U. (Ursula), Remila, L. (Lamia), Chaker, A. (Ahmed Bey), Park, S. (Sinhee), Algara-Suarez, P. (Paola), Belcastro, E. (Eugenia), Jesel, L. (Laurence), Ohlmann, P. (Patrick), Morel, O. (Olivier), Schini-Kerth, V. (Valerie), Nanomédecine Régénérative (NanoRegMed), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie [Strasbourg], CHU Strasbourg, and Auger, Cyril

Subjects
Male, Physiology, Aucun, Empagliflozin, Vascular Cell Adhesion Molecule-1, Blood Pressure, SGLT2, SGLT1, Sodium-Glucose Transporter 1, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Glucosides, Sodium-Glucose Transporter 2, Animals, Benzhydryl Compounds, Rats, Wistar, Sodium-Glucose Transporter 2 Inhibitors, Pharmacology, Angiotensin II, Diastolic dysfunction, Endothelial cell activation, Endothelial Cells, Fibrosis, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Rats, Matrix Metalloproteinase 9, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Hypertension, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Molecular Medicine, Matrix Metalloproteinase 2, Collagen, Atrial Natriuretic Factor
Abstract

SGLT2 inhibitors (SGLT2i) showed pronounced beneficial effects in patients with heart failure but the underlying mechanisms remain unclear. We evaluated the effect of empagliflozin, selective SGLT2i, on hypertension-induced cardiac and vascular dysfunction. Male Wistar rats received diet with or without empagliflozin (30 mg/kg/day). After 1 week, a hypertensive dose of Ang II (0.4 mg/kg/day) was administered using osmotic mini-pumps for 4 weeks. Systolic blood pressure was determined by sphygmomanometry, the cardiac function by echocardiography and ex vivo (coronary microvascular endothelial cell activation, LV remodeling and fibrosis responses), and the systemic micro and macrovascular endothelial cell activation ex vivo. Empagliflozin treatment did not affect the Ang II-induced hypertensive response. Ang II treatment increased LV mass and induced LV diastolic dysfunction, fibrosis, collagen I and ANP expression, and infiltration of macrophages. In the vasculature, it caused eNOS upregulation in the aorta and down-regulation in mesenteric microvessels associated with increased oxidative stress, ACE, AT1R, VCAM-1, MCP-1, MMP-2, and MMP-9 and collagen I expression, increased endothelial SGLT1 staining in the aorta, mesenteric and coronary microvessels, increased SGLT1 and 2 protein levels in the aorta. All Ang II-induced cardiac and vascular responses were reduced by the empagliflozin treatment. Thus, the SGLT2i effectively attenuated the deleterious impact of Ang II-induced hypertension on target organs including cardiac diastolic dysfunction and remodeling, and endothelial cell activation and pro-atherosclerotic, pro-fibrotic and pro-remodeling responses in macro and microvessels despite persistent hypertension.

Published
2022
Full Text
View/download PDF

2. Association of peripartum management and high maternal blood loss at cesarean delivery for placenta accreta spectrum (PAS): A multinational database study

Author

Schwickert, A. (Alexander), Beekhuizen, H.J. (Heleen) van, Bertholdt, C. (Charline), Fox, K.A. (Karin A.), Kayem, G. (Gilles), Morel, O. (Olivier), Rijken, M.J. (Marcus J.), Stefanovic, V. (Vedran), Strindfors, G. (Gita), Weichert, A. (Alexander), Weizsaecker, K. (Katharina), Braun, T. (Thorsten), Calda, P. (Pavel), Chalubinski, K.M. (Kinga M.), Chantraine, F. (Frederic), Collins, S. (Sally), Duvekot, J.J. (Hans), Gronbeck, L. (Lene), Henrich, W. (Wolfgang), Martinelli, P. (Pasquale), Mhallem Gziri, M. (Mina), Morlando, M. (Maddalena), Nonnenmacher, A. (Andreas), Paavonen, J. (Jorma), Pateisky, P. (Petra), Petit, P. (Philippe), Ropacka, M. (Mariola), Tikkanen, M. (Minna), Schwickert, A. (Alexander), Beekhuizen, H.J. (Heleen) van, Bertholdt, C. (Charline), Fox, K.A. (Karin A.), Kayem, G. (Gilles), Morel, O. (Olivier), Rijken, M.J. (Marcus J.), Stefanovic, V. (Vedran), Strindfors, G. (Gita), Weichert, A. (Alexander), Weizsaecker, K. (Katharina), Braun, T. (Thorsten), Calda, P. (Pavel), Chalubinski, K.M. (Kinga M.), Chantraine, F. (Frederic), Collins, S. (Sally), Duvekot, J.J. (Hans), Gronbeck, L. (Lene), Henrich, W. (Wolfgang), Martinelli, P. (Pasquale), Mhallem Gziri, M. (Mina), Morlando, M. (Maddalena), Nonnenmacher, A. (Andreas), Paavonen, J. (Jorma), Pateisky, P. (Petra), Petit, P. (Philippe), Ropacka, M. (Mariola), and Tikkanen, M. (Minna)

Abstract

Introduction: Placenta accreta spectrum (PAS) carries a high burden of adverse maternal outcomes, especially significant blood loss, which can be life-threatening. Different management strategies have been proposed but the association of clinical risk factors and surgical management options during cesarean delivery with high blood loss is not clear. Material and methods: In this international multicenter study, 338 women with PAS undergoing cesarean delivery were included. Fourteen European and one non-European center (USA) provided cases treated retrospectively between 2008 and 2014 and prospectively from 2014 to 2019. Peripartum blood loss was estimated visually and/or by weighing and measuring of volume. Participants were grouped based on blood loss above or below the 75th percentile (>3500 ml) and the 90th percentile (>5500 ml). Results: Placenta percreta was found in 58% of cases. Median blood loss was 2000 ml (range: 150-20 000 ml). Unplanned hysterectomy was associated with an increased risk of blood loss >3500 ml when compared with planned hysterectomy (adjusted OR [aOR] 3.7 [1.5-9.4], p = 0.01). Focal resection was associated with blood loss comparable to that of planned hysterectomy (crude OR 0.7 [0.2–2.1], p = 0.49). Blood loss >3500 ml was less common in patients undergoing successful conservative management (placenta left in situ, aOR 0.1 [0.0–0.6], p = 0.02) but was more common in patients who required delayed hysterectomy (aOR 6.5 [1.7–24.4], p = 0.001). Arterial occlusion methods (uterine or iliac artery ligation, embolization or intravascular balloons), application of uterotonic medication or tranexamic acid showed no significant effect on blood loss >3500 ml. Patients delivered by surgeons without experience in PAS were more likely to experience blood loss >3500 ml (aOR 3.0 [1.4–6.4], p = 0.01). Conclusions: In pregnant women with PAS, the likelihood of blood loss >3500 ml was reduced in planned vs unplanned cesarean delivery, and when the surgery

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results